Cipla, a global pharmaceutical company has signed a Memorandum of Understanding (MoU) with Russia’s National Immunobiological Company to innovative antiviral medical products for HIV and Hepatitis C treatment and to technology transfer and active pharmaceutical ingredients (API) manufacturing. New drugs production will help to change therapeutic regimens and substantially increase availability of drugs for Russian patients. By 2019 total market share for anti-HIV drugs will increase to 60%.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.
